NCT05897190View on ClinicalTrials.gov

Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 16, 2022

Primary Completion Date

June 13, 2022

Study Completion Date

May 12, 2023

Conditions
SARS-CoV-2
Interventions
BIOLOGICAL

SARS-CoV-2 mRNA vaccine (RBMRNA-405)

Dose A

BIOLOGICAL

CoronaVac®

Dose B

Trial Locations (1)

Unknown

Chengdu Xinhua Hospital affiliated to North Sichuan Medical College, Chengdu

Sponsors
All Listed Sponsors
lead

Argorna Pharmaceuticals Co., LTD

INDUSTRY

NCT05897190 - Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster | Biotech Hunter | Biotech Hunter